Cybin Inc. Common Stock
Cybin Inc. functions as a biopharmaceutical company currently in its clinical development phase, concentrating on the advancement of novel therapeutic agents derived from psychedelic compounds. Its research pipeline includes CYB003, a deuterated psilocybin analog under investigation for major depressive disorder, and CYB004, a deuterated DMT compound being developed to address generalized anxiety disorder.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.89 | $0 | -$36M |
| 2026 Q4 | -0.92 | $0 | -$37M |
| 2025 Q3 | -1.76 | $0 | -$32M |
| 2025 Q2 | -1.94 | $0 | -$49M |
| 2025 Q1 | -1.10 | $0 | -$22M |
| 2025 Q4 | -1.46 | $0 | -$22M |
| 2024 Q3 |
| -0.54 |
| $0 |
| -$27M |
| 2024 Q2 | -2.84 | $0 | -$26M |